Abstract 4244: The efficacy and safety of anti-PD-1 therapy in metastatic sarcomas

Abstract

Abstract Sarcomas are a group of rare and malignant tumors originating from mesenchymal tissue with a variety of cellular subtypes. Although several major standard treatments, including neo-adjuvant and adjuvant chemotherapy, surgery and radiation, have made breakthroughs to improve overall survival, there are few additional effective treatments for metastatic sarcomas that have failed traditional therapy. With the encouraging efficacy of PD-1 monoclonal antibodies in nonresectable or metastatic malignant melanomas and lung cancers, immunosuppressive agents provide new hope for the treatment of sarcomas. We retrospectively collected information from 15 patients with stage IV sarcomas who were treated with a PD-1 inhibitor with or without angiogenesis inhibitor after the failure of traditional treatments, from June 15, 2016 to September 30, 2019. The primary observation endpoint was median progression-free survival (mPFS), and the objective response rate (ORR) and the disease control rate (DCR) were secondary endpoints. Treatment-related adverse events (AEs) were evaluated. Patients were observed until death, loss to follow-up, or the end of the PD-1 inhibitor therapy. The average follow-uptime was 8.47 months (1.97-28.12 months). At 12 weeks, the ORR was 23.1% (3/13) and the DCR was 84.6% (11/13). Finally the overall median PFS was 5.06 months, the ORR was 15.4% (2/13) and the DCR was 61.5% (8/13). Common AEs (occurring with 15 patients) included grade 4 hypertension (n=1, 2.6%), grade 3 leukopenia (n=1,2.6%), grade 2 hand and foot syndrome(HFSR) (n=2, 5.1%), grade 1 reactive capillary hyperplasia (RCCEP) (n=7,17.9%), fatigue and weakness (n=5, 12.8%), digestive dysfunction (n=3,7.7%) and fever (n=3,7.7%). The results indicate that PD-1 inhibitors based therapies are effective, safe and well tolerated in patients with advanced sarcomas. The PD-1 inhibitor combined with anti-angiogenesis agents might provide a new and effective strategy to treat metastatic sarcomas. Citation Format: Jilong Yang. The efficacy and safety of anti-PD-1 therapy in metastatic sarcomas [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4244.